Managing Re-Consent in Long-Term Extension Clinical Trials

As clinical research progresses beyond the primary endpoint, many trials transition into long-term extension (LTE) phases. These studies allow continued access to investigational therapies and further evaluation of long-term safety and efficacy. However, transitioning participants into LTE studies requires fresh ethical oversight — specifically, a formal re-consent process. This tutorial outlines best practices for obtaining re-consent in LTE trials, aligning with GCP, GMP documentation, and regulatory expectations.

What Are Long-Term Extension Studies?

LTE studies are follow-up clinical trials offered to participants who completed a parent study. Objectives may include:

• Monitoring long-term safety and adverse events
• Evaluating durability of efficacy
• Allowing continued therapeutic benefit post primary trial

Why Re-Consent Is Required for LTE Studies:

• The LTE phase often involves new endpoints, risks, or procedures
• Regulatory bodies such as USFDA and EMA mandate a separate informed consent for LTE participation
• Participant autonomy must be preserved; continued participation cannot be assumed
• Study protocol and Investigational Product (IP) characteristics may have evolved

Timing and Process of Re-Consent in LTE Trials:

Step 1: Draft a New Informed Consent Form (ICF)

• Clearly distinguish LTE objectives from the main study
• Include risks associated with prolonged drug exposure
• Mention new procedures or assessments, if any
• Describe duration and participant responsibilities

Step 2: Obtain Ethics Committee/IRB Approval

• Submit LTE protocol and new ICF for ethical review
• Include any updates to the Investigator’s Brochure
• Provide justifications for participant eligibility in LTE

Step 3: Train Investigators and Site Personnel

Staff must be trained on the differences between the main and extension studies. Use SOPs available at Pharma SOP templates to ensure consistency.

Step 4: Conduct Participant Re-Consent

• Offer re-consent before the first LTE visit
• Explain new objectives, risks, and timelines
• Allow time for questions and voluntary decision-making
• Document signed ICF and discussion in source notes

Elements to Include in the LTE Informed Consent Form:

• Statement clarifying LTE as a new study phase
• New data handling and reporting obligations
• Modified withdrawal criteria or safety monitoring plans
• Contact details for queries or complaints
• Updated compensation clauses (if applicable)

Participant Communication Strategies:

• Use layperson language to explain LTE differences
• Highlight changes in benefit-risk ratio
• Assure participants that refusal to participate will not impact routine care
• Use visuals and infographics for better understanding

Documentation and Record Keeping:

• File the signed LTE ICF in participant records
• Log consent in the site’s informed consent tracker
• Retain old ICFs for audit trail and regulatory inspection
• Ensure version control and track updates systematically

Audit and Regulatory Expectations:

Best Practices for Re-Consent in LTE Trials:

1. Start early — initiate LTE discussion during final visits of the main study
2. Prepare a participant handout outlining LTE rationale
3. Ensure ICF readability and comprehension assessments
4. Use AV recording for re-consent in countries like India, as per CDSCO
5. Engage LARs or caregivers when applicable

Challenges and Mitigation:

• Challenge: Participant fatigue or reluctance
• Mitigation: Emphasize continued health monitoring and access to investigational treatment
• Challenge: Delayed EC/IRB approvals
• Mitigation: Submit LTE protocols in parallel with main study closure reports
• Challenge: Multiple ICF versions
• Mitigation: Use version-controlled trackers and standardized forms

Real-World Example:

In a Phase III rheumatoid arthritis study, participants completing 48 weeks of the core study were offered entry into a 2-year LTE trial. New consent forms highlighted prolonged exposure risks, liver enzyme monitoring, and withdrawal flexibility. The IRB mandated re-consent using a clearly marked LTE ICF. As recommended on Stability Studies, detailed documentation was maintained, ensuring transparency and compliance.

Conclusion:

Re-consent in long-term extension studies is not merely an administrative requirement—it is a reaffirmation of the participant’s autonomy and the trial’s commitment to ethical conduct. A clear, timely, and well-documented re-consent process safeguards both participant rights and the integrity of clinical research. By integrating SOPs, staff training, and participant-centered communication, sponsors and sites can manage LTE transitions effectively and compliantly.

Managing Re-Consent and Version Control in Clinical Trials with eConsent Platforms

In decentralized clinical trials (DCTs), protocol amendments, safety updates, and new regulatory findings often require participants to re-consent. Manually managing re-consent and version tracking is time-consuming and error-prone. Digital consent platforms (eConsent) provide a robust solution to streamline re-consent, track version changes, and maintain audit-ready documentation. This tutorial will guide you through implementing and optimizing re-consent and version control using eConsent systems.

Understanding Re-Consent in Clinical Trials

Re-consent refers to obtaining participants’ renewed consent when significant changes occur after initial enrollment, such as:

• Protocol amendments affecting study design or risk
• New safety information or serious adverse events
• Changes to treatment regimens or visit schedules
• Regulatory updates requiring participant notification

According to EMA and CDSCO guidance, sponsors must document each re-consent with time, date, updated content, and participant acknowledgment.

How eConsent Simplifies Re-Consent Workflows

Using an eConsent platform eliminates the logistical challenges of distributing updated paper forms. Benefits include:

• Automated notifications to participants and sites
• Digital signing and acknowledgment of updated versions
• Real-time tracking of who has or hasn’t re-consented
• Centralized version control and archival
• Electronic audit trails for regulatory inspections

This enhances compliance and operational efficiency, especially in multi-site or global trials.

Key Features of Version Tracking in eConsent Systems

1. Version Control Numbering: Each iteration of the consent form is assigned a unique version number and effective date.
2. Audit Trail Integration: Tracks changes from prior versions and records who approved and distributed the updates.
3. Participant Notification System: Sends alerts to patients prompting re-consent with context for changes.
4. Document Locking: Previous versions are locked from editing and retained for GCP compliance.
5. Regulatory Archiving: All versions and signatures are stored with metadata for future audits.

As required by GMP documentation best practices, these features ensure traceability and accountability.

Step-by-Step: Executing a Re-Consent in eConsent

Step 1: Identify the Need for Re-Consent

Trigger events can include protocol amendments, safety updates, or investigator site changes. The sponsor should collaborate with the medical monitor and regulatory affairs to determine if re-consent is required.

Step 2: Prepare the Updated Consent Document

Revise the ICF in plain language. Use track changes to highlight new or updated sections. Run translations if required for multilingual populations. Validate the updated form through your validation protocol.

Step 3: Upload and Release in the eConsent Platform

• Assign a new version number (e.g., V2.1)
• Set release and expiry dates
• Enable participant view and acknowledgment
• Restrict prior versions from further signing

Step 4: Notify Sites and Participants

eConsent tools should send secure emails or in-app alerts. Investigators receive a checklist of pending re-consents for follow-up. Participants access the updated form through web or mobile interfaces with guided explanations.

Step 5: Track Completion and Compliance

• Monitor real-time dashboards showing % re-consent completion
• Send automated reminders to those pending
• Generate exception reports for protocol deviation tracking

Best Practices for Managing Re-Consent Digitally

• Include re-consent workflow in the initial protocol and SOP checklist
• Always lock prior versions once a new version is deployed
• Provide summaries of changes to improve participant comprehension
• Use system-generated audit trails to show who consented, when, and on what version
• Test re-consent flow during UAT of the eConsent system
• Retain all versions for a minimum of 15 years, or as per local law

Example: eConsent Re-Consent in a Phase III Oncology Trial

After a protocol amendment added a new biomarker analysis, re-consent was required. The eConsent platform was configured to:

• Upload ICF Version 3.0
• Notify 200 participants across 10 countries
• Provide language-specific updates and explanations
• Track completion via a centralized dashboard

Result: 95% re-consent within 5 business days, zero protocol deviations, and full audit readiness as per USFDA inspection expectations.

Common Challenges and Solutions

• Delay in Re-Consent: Use automated reminders and progress dashboards to accelerate completion
• Confusion from Multiple Versions: Always disable signing for outdated forms and clearly label versions
• Cross-country Consent Issues: Ensure translated versions are ready and validated before release

Why This Matters for Decentralized Trials

In DCTs, participants may never visit a physical site. Paper re-consent is impractical. eConsent ensures rapid, compliant, and participant-friendly re-consenting even in the most distributed trial models. This is essential to maintain ethical standards and regulatory confidence.

Conclusion

Re-consent and version tracking are critical aspects of informed consent management in clinical trials. eConsent platforms streamline these functions while enhancing participant engagement, data traceability, and inspection readiness. Sponsors should leverage these digital capabilities to support GCP compliance, operational efficiency, and ethical trial conduct in modern decentralized models.